VACCINEX, INC. (VCNX): Nasdaq/NYSE listing notice — Vaccinex receives Nasdaq delisting notice; trading suspended Dec 18, 2024

VACCINEX, INC.

Nasdaq Hearings Panel determined to delist VCNX for failing to maintain $2.5M minimum stockholders' equity.
Trading suspension effective at open of trading on Wednesday, December 18, 2024.
Company expects common stock to be quoted on OTC Markets Group under symbol VCNX.
Press release issued December 17, 2024 announcing the delisting determination.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

VACCINEX, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

December 16, 2024, Vaccinex, Inc. (the “Company”) received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice indic

View on SEC.gov

Browse all listing & compliance notices →

VACCINEX, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-280155

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.